Drugs /

jab-3312

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable inhibitor of the KRAS-mitogen-activated protein kinase (MAPK) signaling pathway, with potential antineoplastic activity. Upon oral administration, JAB-3312 blocks signaling through the KRAS-MAPK pathway. This prevents proliferation of susceptible cancer cells in which the KRAS-MAPK signaling pathway is overactivated. The Ras-MAPK pathway is often hyperactivated in cancer cells due to specific mutations and rearrangements, such as those seen in KRAS-mutant cancer cells, and drives cancer cell proliferation and survival.

Clinical Trials

View Clinical Trials for jab-3312

Jab-3312 has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating jab-3312, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open).

Malignant solid tumor is the most common disease being investigated in jab-3312 clinical trials [2].

Drug Details

Synonyms [2]:
jab 3312, jab3312, kras-mapk signaling pathway inhibitor jab-3312
Drug Target(s) [2]:
PTPN11
NCIT ID [1]:
C164218

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.